PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
Recruiting · NCT06617481 · Interventional (participants receive a specific treatment) · Lead sponsor: AdventHealth
View the official record on ClinicalTrials.gov →Interventions studied
18F-rhPSMA-7.3 (Posluma)
What this trial is about
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- History of localized adenocarcinoma of the prostate with prior curative intent radical prostatectomy.
- An elevated PSA test result that is greater than or equal to 0.1 ng/ml and less than 0.5
Exclusion criteria
- Patients who are planned to have an x-ray contrast agent or other PET radiotracer \& less than 24 hours prior to the flotufolastat F-18 PSMA-PET scan.
- Patients currently receiving Androgen Deprivation Therapy (ADT).
Where it is running
1 location listed across 1 US state.
- AdventHealth - Orlando, Florida, United States